loading
Prothena Corporation Plc stock is traded at $8.77, with a volume of 1.23M. It is up +2.45% in the last 24 hours and up +34.30% over the past month. Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$8.56
Open:
$8.63
24h Volume:
1.23M
Relative Volume:
0.80
Market Cap:
$472.09M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-8.77
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+6.30%
1M Performance:
+34.30%
6M Performance:
-43.64%
1Y Performance:
-58.73%
1-Day Range:
Value
$8.52
$8.97
1-Week Range:
Value
$8.28
$8.97
52-Week Range:
Value
$4.32
$22.83

Prothena Corporation Plc Stock (PRTA) Company Profile

Name
Name
Prothena Corporation Plc
Name
Phone
011-353-1-236-2500
Name
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Name
Employee
163
Name
Twitter
@ProthenaCorp
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
PRTA's Discussions on Twitter

Compare PRTA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRTA
Prothena Corporation Plc
8.77 459.17M 217.25M -50.92M -100.85M -1.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades

Date Action Analyst Rating Change
May-28-25 Downgrade BofA Securities Neutral → Underperform
May-27-25 Downgrade Cantor Fitzgerald Overweight → Neutral
May-27-25 Downgrade Jefferies Buy → Hold
May-27-25 Downgrade Oppenheimer Outperform → Perform
Dec-20-24 Initiated Chardan Capital Markets Buy
Jan-30-24 Downgrade BofA Securities Buy → Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Apr-24-23 Initiated SVB Securities Outperform
Jan-27-23 Initiated Piper Sandler Overweight
Nov-04-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-28-22 Upgrade BofA Securities Neutral → Buy
Nov-19-21 Initiated JMP Securities Mkt Outperform
Jun-18-21 Upgrade BofA Securities Underperform → Neutral
Jun-08-21 Reiterated Oppenheimer Outperform
May-26-21 Initiated Citigroup Buy
Feb-26-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-12-21 Upgrade Jefferies Hold → Buy
Feb-02-21 Upgrade BTIG Research Neutral → Buy
Dec-07-20 Initiated H.C. Wainwright Buy
Jul-09-20 Upgrade Oppenheimer Perform → Outperform
Nov-19-19 Upgrade Evercore ISI In-line → Outperform
May-21-18 Downgrade Barclays Equal Weight → Underweight
Apr-23-18 Downgrade Jefferies Buy → Hold
Apr-05-18 Reiterated Barclays Overweight
Nov-20-17 Downgrade Wedbush Outperform → Neutral
Sep-29-17 Reiterated BTIG Research Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Aug-17-17 Initiated Evercore ISI Outperform
Jul-11-17 Initiated Jefferies Buy
Apr-12-17 Initiated Cantor Fitzgerald Overweight
Apr-12-17 Initiated Piper Jaffray Overweight
Mar-02-17 Initiated Instinet Buy
Dec-21-16 Initiated SunTrust Buy
Nov-03-16 Initiated Deutsche Bank Buy
Aug-04-16 Reiterated Barclays Overweight
May-13-16 Initiated Barclays Overweight
Feb-19-16 Reiterated Wedbush Outperform
Jan-21-16 Initiated Credit Suisse Outperform
View All

Prothena Corporation Plc Stock (PRTA) Latest News

pulisher
Aug 20, 2025

Prothena Corporation plc stock outlook for YEARPortfolio Profit Report & High Win Rate Trade Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Strategies to average down on Prothena Corporation plcJuly 2025 Update & Short-Term High Return Ideas - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Is Prothena Corporation plc still worth holding after the dipWeekly Trend Report & Intraday High Probability Setup Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

How institutional ownership impacts Prothena Corporation plc stockWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Can swing trading help recover from Prothena Corporation plc lossesWeekly Stock Recap & Consistent Growth Equity Picks - Newser

Aug 20, 2025
pulisher
Aug 19, 2025

Tick level data insight on Prothena Corporation plc volatilityBuy Signal & Free Weekly Chart Analysis and Trade Guides - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Using data models to predict Prothena Corporation plc stock movement2025 Volume Leaders & AI Driven Stock Movement Reports - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Earnings visualization tools for Prothena Corporation plcQuarterly Market Review & Real-Time Stock Price Movement Reports - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Is Prothena Corporation plc trending in predictive chart modelsMarket Risk Analysis & Short-Term High Return Ideas - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Relative strength of Prothena Corporation plc in sector analysisJuly 2025 Catalysts & Safe Capital Investment Plans - Newser

Aug 19, 2025
pulisher
Aug 17, 2025

Ranking Prothena Corporation plc among high performing stocks via tools2025 Technical Overview & Stock Portfolio Risk Management - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Will a bounce in Prothena Corporation plc offer an exitPortfolio Update Summary & Target Return Focused Stock Picks - Newser

Aug 17, 2025
pulisher
Aug 15, 2025

Key resistance and support levels for Prothena Corporation plcPrice Action & Expert Curated Trade Ideas - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Will Prothena Corporation plc see short term momentum2025 Trading Recap & Growth Focused Entry Reports - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Recovery Signals Appearing in Prothena Corporation plc Charts2025 Macro Impact & High Conviction Buy Zone Picks - beatles.ru

Aug 15, 2025
pulisher
Aug 14, 2025

Is Prothena Corporation plc Forming a Consolidation Base2025 Historical Comparison & Accurate Buy Signal Alerts - beatles.ru

Aug 14, 2025
pulisher
Aug 14, 2025

Prothena Corporation plc Stocks Attracting Dip Buyers2025 Support & Resistance & Accurate Intraday Trade Tips - newsyoung.net

Aug 14, 2025
pulisher
Aug 14, 2025

Published on: 2025-08-14 23:29:29 - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes By Investing.com - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes - Investing.com

Aug 14, 2025
pulisher
Aug 12, 2025

Can trapped investors hope for a rebound in Prothena Corporation plcFree Investment Strategy With Low Risk - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

What MACD signals say about Prothena Corporation plcForecast Model for Intraday Buy Signals - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

How to escape a deep drawdown in Prothena Corporation plcFree Low Risk High Return Opportunities - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

How to build a dashboard for Prothena Corporation plc stockSummary of Reliable Long-Term Trade Models - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Building trade automation scripts for Prothena Corporation plcBreakout Stock Opportunities with Low Drawdown - Newser

Aug 12, 2025
pulisher
Aug 11, 2025

Volume spikes in Prothena Corporation plc stock – what they meanFree Safe Entry Stock Watch Suggestions - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

How Prothena Corporation plc stock performs during market volatilityLow Exposure Strategy with Sector Analysis - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

Trend Reversal Possible in Prothena Corporation plc Charts IndicateSmart Allocation Stock Pick Insights Gaining Interest - metal.it

Aug 10, 2025
pulisher
Aug 08, 2025

Royal Bank Of Canada Cuts Prothena (NASDAQ:PRTA) Price Target to $10.00 - Defense World

Aug 08, 2025
pulisher
Aug 07, 2025

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - BioSpace

Aug 07, 2025
pulisher
Aug 06, 2025

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful - Investing.com India

Aug 06, 2025
pulisher
Aug 06, 2025

Prothena (PRTA) Surges on Novo Nordisk's Phase 3 Plans for ATTR Amyloidosis Drug - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk - TipRanks

Aug 06, 2025
pulisher
Aug 06, 2025

Prothena Announces that Novo Nordisk Will Advance Coramitug (For - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan

Aug 06, 2025
pulisher
Aug 06, 2025

Applying sector rotation models to Prothena Corporation plcFree Swing Trading Entry Point Signals - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Prothena announces that Novo Nordisk will advance Coramitug into phase 3 development - MarketScreener

Aug 06, 2025
pulisher
Aug 05, 2025

Prothena stock price target lowered to $10 at RBC on program discontinuation By Investing.com - Investing.com South Africa

Aug 05, 2025
pulisher
Aug 05, 2025

Prothena stock price target lowered to $10 at RBC on program discontinuation - Investing.com Nigeria

Aug 05, 2025
pulisher
Aug 05, 2025

PRTA: RBC Capital Maintains Rating, Lowers Price Target | PRTA S - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

9 Analysts Assess Prothena Corp: What You Need To Know - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

Prothena’s Losses Grow As Revenue Drops And Programs Wind Down - Finimize

Aug 05, 2025
pulisher
Aug 05, 2025

RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Prothena Corp (PRTA) Maintains 'Buy' Rating with $18 Target by C - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

JMP reiterates Market Outperform rating on Prothena stock ahead of key data - Investing.com Nigeria

Aug 05, 2025
pulisher
Aug 05, 2025

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - BioSpace

Aug 05, 2025
pulisher
Aug 05, 2025

Prothena Reports Q2 2025 Financial Results and Pipeline Progress - TipRanks

Aug 05, 2025

Prothena Corporation Plc Stock (PRTA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Prothena Corporation Plc Stock (PRTA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
EcoR1 Capital, LLC
10% Owner
May 06 '25
Sale
7.64
1,984,053
15,164,712
5,304,596
EcoR1 Capital, LLC
10% Owner
May 05 '25
Sale
8.11
977,693
7,930,166
7,288,649
SCULLY WILLIAM P
10% Owner
Jan 14 '25
Buy
12.79
100,000
1,279,040
735,993
SCULLY WILLIAM P
10% Owner
Dec 18 '24
Buy
13.93
73,436
1,022,670
1,297,693
SCULLY WILLIAM P
10% Owner
Dec 31 '24
Buy
13.01
32,000
416,393
650,193
SCULLY WILLIAM P
10% Owner
Dec 20 '24
Buy
15.91
2,000
31,813
618,693
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):